Tempest to Present Biomarker Data for TPST-1120 at the Society for Immunotherapy of Cancer (SITC) 2023 Spring Scientific Meeting

Rhea-AI Summary

Tempest Therapeutics, Inc. (Nasdaq: TPST) announced a poster presentation by Dr. Nathan Standifer at the Society for Immunotherapy of Cancer (SITC) 2023 Spring Meeting from March 15-17 in Denver, CO, and online. The presentation will detail biomarker findings from the Phase 1 trial of TPST-1120, an oral selective PPAR⍺ antagonist. Key data indicate a link between clinical benefits and changes in fatty acid oxidation and gene expression. The presentation is scheduled for March 16, 2023, from 6:00 to 7:30 p.m. MT, and carries the abstract number 78. Tempest Therapeutics is focused on developing innovative oncology therapeutics that target various tumors.

BRISBANE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class¹ therapeutics that combine both targeted and immune-mediated mechanisms, today announced that Nathan Standifer Ph.D., Executive Director of Translational Science at Tempest, will present a poster at the Society for Immunotherapy of Cancer (SITC) 2023 Spring Scientific Meeting taking place March 15-17, 2023 in Denver, CO and virtually. The poster highlights biomarker data from the Phase 1 trial of TPST-1120, an oral selective PPAR⍺ antagonist, showing an association between observed clinical benefit and fatty acid oxidation perturbations and gene expression.

Poster presentation details:
Title:	TPST-1120, a first-in-human peroxisome-proliferator activated receptor-alpha (PPAR-α) antagonist: scientific rationale, clinical activity and biomarker assessments
Date:	Thursday, March 16, 2023
Time:	6:00 - 7:30 p.m. MT
Abstract Number:	78

About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company has a diverse portfolio of novel programs ranging from early research to investigation in a randomized global study in first-line cancer patients. The company’s two novel clinical programs TPST-1120 and TPST-1495, target of PPARα and EP2/EP4, respectively, are advancing through trials designed to study the agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally available inhibitor of TREX1, a target that controls activation of the cGAS/STING pathway. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at www.tempesttx.com.

Investor Contacts:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com

Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

____________________

¹ If approved by the FDA

FAQ

What is the purpose of the TPST-1120 presentation at SITC 2023?

The TPST-1120 presentation discusses biomarker data from its Phase 1 trial, showing a connection between clinical benefits and fatty acid oxidation changes.

When is the TPST-1120 presentation scheduled at the SITC 2023 meeting?

The presentation is scheduled for March 16, 2023, from 6:00 to 7:30 p.m. MT.

What type of drug is TPST-1120?

TPST-1120 is an oral selective PPAR⍺ antagonist being tested for its oncology applications.

Where is the SITC 2023 Spring Scientific Meeting taking place?

The SITC 2023 Spring Scientific Meeting is taking place in Denver, CO, and virtually.

What significant findings will be presented for TPST-1120?

Findings indicate an association between observed clinical benefits and alterations in fatty acid oxidation and gene expression.